NLR, ELR and SII Index as Biomarkers of Asthma Control
ConditionAsthma Control
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShaimaa Ali Mohammed
About this trial
This is Case control study aims to study Neutrophil-to-Lymphocyte Ratio (NLR), Eosinophil-to-Lymphocyte Ratio (ELR), and Systemic Immune Inflammation (SII) Index as Biomarkers of Asthma Controlin adult patients with bronchial asthma.
This study will investigate the association between these inflammatory indices and the level of asthma control to assess their potential value as simple ,readily available and cost -effective biomarkers in clinical practice.
Eligibility criteria
Qualifiers
Adult patients aged > 18 years.
Confirmed diagnosis of bronchial asthma according to Global Initiative for Asthma (GINA) guidelines.
Patients who provided informed consent to participate in the study.
Disqualifiers
Patients with chronic respiratory diseases other than asthma.
Acute respiratory infection within the previous 4 weeks.
Patients with hematological disorders, malignancies, autoimmune diseases, or systemic inflammatory conditions that might affect blood cell counts.
Patients taking systemic steroids, experiencing acute asthma attack (because infection may affect neutrophil level).
Trial design
Treatments tested in this trial
- Complete blood count
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Shaimaa Ali Mohammed
Lead sponsor
Assiut University
Sponsor institution
Source ClinicalTrials.gov